These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25246268)

  • 1. Interleukin 21 blockade modulates activated T- and B-cell homeostasis via B-cell activating factor pathway-mediated inhibition in a murine model of acute graft-versus-host disease.
    Lim JY; Park MJ; Im KI; Kim N; Park HS; Lee SH; Kim EK; Nam YS; Lee ES; Cho ML; Cho SG
    Exp Hematol; 2015 Jan; 43(1):23-31.e1-2. PubMed ID: 25246268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
    Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-22 aggravates murine acute graft-versus-host disease by expanding effector T cell and reducing regulatory T cell.
    Zhao K; Zhao D; Huang D; Yin L; Chen C; Pan B; Wu Q; Li Z; Yao Y; Shen E; Zeng L; Xu K
    J Interferon Cytokine Res; 2014 Sep; 34(9):707-15. PubMed ID: 24720737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
    Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
    Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells.
    Okamoto S; Fujiwara H; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Yoshimura A; Tanimoto M; Maeda Y
    J Immunol; 2015 Feb; 194(3):1357-63. PubMed ID: 25527789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
    Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS; Rus V; Nguyen P; Linsley P; Gause WC
    J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
    Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
    J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Tanaka J; Imai K; Han M; Fujii Y; Kobayashi M; Higa T; Kasai M
    Immunobiology; 1994 Jun; 190(4-5):346-67. PubMed ID: 7982720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease.
    Shao L; Lie AK; Zhang Y; Wong CH; Kwong YL
    Ann Hematol; 2015 Sep; 94(9):1493-504. PubMed ID: 25963280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.